NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

A Study of CTD402 in T-ALL/LBL Patients

RecruitingPhase 1, Phase 2

Sponsor: Imviva Bio

Conditions: Acute Lymphocytic Leukemia Refractory, Lymphoma, Lymphoblastic

Interventions: CTD402 CAR T Cell Injection

Countries: United States, Australia

The goal of the TENACITY-01 clinical trial is to learn if CTD402 UCART is safe and effective for relapsed/refractory T-ALL/LBL patients. Participants with relapsed/refractory T-ALL/LBL over the age of 1 year will be eligible to participate. Participants will receive one infusion of CTD402 on Day 0 and will be evaluated for anti-tumor activity by an independent review committee based on the NCCN criteria for T-ALL and the Lugano 2014 criteria for T-LBL. Patients will be followed for up to 24 months in this study and will be required to enroll under a separate long term follow up protocol to be followed for up to 15 years.

Eligibility overview

Sex: ALL

Age: 1 Year to —

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Key Inclusion Criteria:

1. Male or female, ≥ 1 year of age.
2. Participants with body weight ≥ 40 kilogram.
3. A) Relapsed or refractory T-ALL/LBL or MRD positive defined as one of the following:

* Relapsed or refractory disease after two or more lines of systemic therapy;
* The first relapse occurs within 12 months after first remission;
* Relapse after allogeneic HSCT and must be ≥100 days from HSCT prior to screening period.

B) Minimal Residual Disease (MRD) positive T-ALL/LBL is defined as evidence of MRD, defined as \< 5% blasts in bone marrow but ≥ 1 cancer cell in 1,000 cells determined by NGS ClonoSEQ® and/or other regionally acceptable methodologies (e.g., EuroMRD guidelines).
4. The presence of bone marrow lymphoblasts is ≥ 5% as determined by morphologic evaluation or evidence of extramedullary disease at screening.
5. Adequate organ function
6. ECOG of 2 or less or Karnofsky PS ≥ 60 (for participants age ≥ 16) or Lansky PS ≥ 60 (for participants \< 16) at screening.

Key Exclusion Criteria:

1. Participants with concomitant genetic syndromes associated with bone marrow failure states or any other known bone marrow failure syndrome.
2. Active central nervous system (CNS) involvement
3. Participants with following cardiac conditions will be excluded:

1. History of heart failure New York Heart Association (NYHA) class III or IV;
2. History of myocardial infarction, cardiovascular angioplasty or stenting, unstable angina, or other serious heart diseases within 12 months of enrollment.
4. Primary immune deficiency.
5. Presence of uncontrolled infections.
6. Known history of infection with the human immunodeficiency virus (HIV); hepatitis C virus and syphilis.
7. Active or latent hepatitis B virus infection
8. Epstein-Barr virus (EBV), Cytomegalovirus (CMV) DNA or IgM positive at screening.

Locations (9)

Palo Alto, California, United States
Denver, Colorado, United States
Chicago, Illinois, United States
Rochester, Minnesota, United States
New York, New York, United States
The Bronx, New York, United States
Nashville, Tennessee, United States
Houston, Texas, United States
Sydney, New South Wales, Australia